The list of emerging and reemerging pathogens that cause neurologic disease is expanding. Various factors, including population growth and a rise in international travel, have contributed to the spread of pathogens to previously nonendemic regions. Recent advances in diagnostic methods have led to the identification of novel pathogens responsible for infections of the central nervous system. Furthermore, new issues have arisen surrounding established infections, particularly in an increasingly immunocompromised population due to advances in the treatment of rheumatologic disease and in transplant medicine.
Emerging and Reemerging Neurologic Infections
The list of emerging and reemerging pathogens that cause neurologic syndromes is growing. Not only have advances in diagnostic methods led to the identification of novel pathogens but also several recognized pathogens have expanded their geographic distribution into previously nonendemic regions. Unprecedented spread of a number of arboviruses is attributable to human population growth, changes in agriculture practices (eg, rice farming and pig farming), and a dramatic rise in international travel. And finally, even for established pathogens, new issues have emerged in an increasingly immunocompromised population due to advances in the treatment of rheumatologic disease and transplant medicine.
In this article, we will review key emerging and reemerging pathogens that cause neurologic disease. We chose to focus on neurologic diseases that fall into 2 major categories of ''emerging'' infections. In the first category, we include newly discovered pathogens that typically cause acute neurologic syndromes and may be encountered in the inpatient setting, but of which neurohospitalists may be unaware. In the second category, we highlight novel issues that have recently emerged around established neurologic infections. Many of these pathogens result in nonspecific neurologic symptoms with tremendous overlap in clinical presentation. As a result, being familiar with their epidemiology is essential to diagnosis. For example, certain infections (eg, Nipah and Hendra) are exceedingly rare, but in the setting of travel to affected regions of the world (eg, Asia and Australia, respectively) and specific exposures, they should be seriously considered and tested.
Conversely, infections with free-living amoeba are similarly rare but can be acquired in one's own backyard and should be considered when the epidemiologic and clinical characteristics fit. Given the potential increasing clinical and public health relevance of these emerging and reemerging infections, neurohospitalists should be familiar with these pathogens to aid in prompt recognition and appropriate care.
Viral

Enterovirus 71
Enterovirus 71 (EV71), a member of the Enterovirus genus within the Picornaviridae family first isolated in California over 40 years ago, 1, 2 has recently emerged as a cause of large outbreaks of infection, primarily in young children. The Asia Pacific has been hardest hit with hundreds of thousands of reported cases in epidemic years, 3, 4 although countries worldwide, including the United States and Australia, [5] [6] [7] have seen clusters of infection.
Enterovirus 71, which peaks in summer and fall, is usually heralded by a prodromal illness of fever with or without other Parechoviruses Reclassification of former enteroviruses, echovirus 21 and echovirus 22, resulted in the human parechovirus (HPeV) genus. Echoviruses 21 and 22 are currently classified as HPeV-1 and HPeV-2, respectively. At least 12 HPeV serotypes have been described to date; nearly all have been associated with encephalitis, typically in children less than 2 years of age. 17, 18 Clusters of HpeV3 central nervous system (CNS) infections have been reported. 19 Young children and infants with HPeV encephalitis develop fever, seizures, irritability, feeding difficulties, and rash. 20 The relative frequency of HPeV encephalitis is unknown, particularly because HPeV testing has only recently become available (Table 1) .
West Nile Virus
West Nile virus (WNV), a member of the Flavivirus genus, is the leading cause of neuroinvasive arboviral disease in the United States. 21 First isolated in the West Nile region of Uganda, 22 WNV is widely distributed throughout the world, including in Africa, Europe, the Middle East, and Western Asia. Since its Western hemisphere debut in New York City in 1999, 23 WNV has spread throughout the country and is now endemic in the continental United States. 24 In 2012, 5674 human cases of WNV were reported to the Centers for Disease Control and Prevention (CDC), approximately half of which were neuroinvasive, 24 making it the second worst outbreak of WNV after the 2003 epidemic which involved 9862 cases. The cause of the increase in cases in 2012 is unclear, although warmer temperatures, which result in increased viral replication and a shorter incubation period in mosquitoes, may have contributed. 25, 26 An estimated 25% of individuals infected with WNV develop symptoms including fever, headache, generalized weakness, myalgias, and rash. 27 Severe neuroinvasive disease, which occurs in less than 1% of infected individuals, can manifest as meningitis, encephalitis, or flaccid paralysis. 28 Older age, history of alcohol abuse, cancer, chronic renal disease, diabetes mellitus, and hypertension have been identified as risk factors for neuroinvasive disease. 29 Diagnostic testing for WNV is available in many laboratories. Immunoglobulin (Ig) M antibody seroconversion, which often coincides with the onset of symptoms, tends to occur 7 to 8 days after a mosquito bite, while IgG antibodies appear a median of only 3.4 days later. 30 Immunoglobulin M antibodies in the serum and CSF can remain positive for months to more than a year from the time of infection. [30] [31] [32] Patients with a positive IgM and negative IgG antibody test may be within the narrow window of hyperacute infection, whereas a negative IgM antibody test in conjunction with a positive IgG indicate prior infection.
Powassan Virus
Powassan virus (POWV), a tick-borne flavivirus, causes encephalitis in North America. About 50 cases of POWV have been reported to the CDC in the past 10 years. 33 Until recently, most cases have been reported from the northeastern United States. Since 2008, however, an increasing number of cases have been reported in Minnesota and Wisconsin. 34 Patients often experience a viral prodrome with fever and headache. When encephalitis occurs, mental status changes, seizures, cerebellar symptoms, and hemiplegia are described. Diagnostic testing is available at the CDC.
Japanese Encephalitis Virus
Japanese encephalitis virus (JEV) is the leading cause of encephalitis worldwide with an estimated 67 900 annual cases. The highest burden of disease occurs in Korea, China, India, and Indonesia. 35 Japanese encephalitis virus is considered an emerging pathogen due to significant geographic expansion in recent years. Despite a safe and effective vaccine, its use has been primarily in small and high-income Asian countries. 36 Like other arboviruses, many JEV infections are asymptomatic. Indeed, less than 1% of JEV infections leads to clinical disease. When symptoms occur, encephalitis is the most common presentation. Illness often begins with a febrile prodrome of headache and vomiting followed by mental status changes along with seizures, focal neurologic deficits, or movement disorders. Features of parkinsonism with masklike facies, cogwheel rigidity, and choreoathetoid movements are particularly characteristic of JEV. 37 Similar to patients with WNV, those affected by JEV can also develop acute flaccid paralysis. 38 The overall case fatality rate is 20% to 30% and neurologic sequelae occur in 30% to 50% of cases. 39, 40 While it is the leading cause of encephalitis worldwide, the overall risk of JEV is low for travelers to affected regions. Less than 1 case per 1 million travelers has been noted. 40, 41 Only 19 cases have been reported in the United States since 1973; these include a very recent case series of 3 adults who contracted JEV while visiting Asia. 42 Nevertheless, JEV should be considered in travelers returning from affected countries, particularly if travel was in rural and agricultural areas, with compatible clinical features. 41 Diagnosis of JEV is generally by serologic methods, and testing is available at the CDC (Table 1) .
Tick-Borne Encephalitis
Tick-borne encephalitis virus (TBEV), closely related to POWV, is one of the most common causes of arboviral encephalitis in Europe and Russia. 43 Its geographic range has expanded to include China and Japan. Due to better diagnostic assays, improved case reporting, and increased recreational activities in tick-infested areas, the number of recognized cases has risen dramatically. In Europe and Russia, an average of 2755 cases per year occurred from 1976 to 1989 compared with 8755 cases per year from 1990 to 2007. 44 Tick-borne encephalitis virus is characterized by 3 different subtypes: European (TBEV-Eu), Siberian (TBEV-Sib), and Far Eastern (TBEV-Fe). The TBEV-Eu subtype circulates predominantly in Western, Central, Northern, and Eastern Europe, while the TBEV-Sib circulates predominantly in Asian parts of Russia and TBEV-Fe circulates predominantly in China, Japan, and Eastern Russia. The clinical manifestations range from mild meningitis to severe meningoencephalitis with or without myelitis and paralysis. 45 Analogous to WNV, neuroinvasive disease is more common in older populations. In individuals affected with the TBEV-Eu subtype, the illness is often 
Toscana Virus
Toscana virus (TV), a member of the Phlebovirus genus within the Bunyaviridae family transmitted by the sandfly, is one of the most common causes of meningoencephalitis in the summer months in the Mediterranean. 47 In 1 study in Tuscany, Italy, more than half of the cases of aseptic meningoencephalitis over a 7-year period were attributed to TV. 48 Seroprevalence rates of anti-TV IgG antibodies may be as high as 26%. [49] [50] [51] Few cases of Toscana infections in the United States in returning travelers have been reported. 52, 53 Overall, the natural history of TV meningoencephalitis is considered to be relatively benign with a self-limited course. A review of all cases of TV meningoencephalitis reported in the English literature between 1971 and 2012 revealed 42 patients, 3 of whom were diagnosed in the United States. Compared to other common causes of meningoencephalitis in the United States (EV, herpes simplex virus [HSV], and WNV), patients with TV were more likely to present with classic symptoms and signs associated with meningitis, including fever in 97% (compared with HSV and WNV), headache in 100% (compared with EV and WNV), stiff neck in 87% (compared with all 3 other viruses), photophobia in 86% (compared with EV and WNV), and nuchal rigidity in 89% (compared with all 3 viruses). Interestingly, 44% of patients with TV also presented with signs/symptoms consistent with encephalitis, comparable to the proportion of patients with HSV and WNV infections. Cerebrospinal fluid profile demonstrated a moderate pleocytosis (median white blood cell count 208 cells/mm 3 ), mildly elevated protein (median protein 88 mg/dL), and normal glucose. Brain imaging is typically normal, although hydrocephalus was present in 15% of cases who underwent magnetic resonance imaging. A poor neurologic outcome, defined as a Glasgow outcome score ranging from 1 (death) to 4 (moderate disability), occurred in 2 (8%) of the 25 patients with TV compared with 15 (50%) of the 30 for WNV. Detection of IgM antibodies, isolation of virus from CSF, and reverse transcription PCR are the most common laboratory techniques for confirming the diagnosis of TV (Table 1 ). 47 
Chikungunya Virus
Chikungunya virus (CHIKV) is an emerging and reemerging mosquito-born alphavirus associated with high attack rates and potential for rapid, exponential, and sustained transmission during outbreaks. First described in the Makonde Plateau in Eastern Africa in the mid 20th century, 54 the virus has since caused sporadic and epidemic cases throughout Africa and Asia. 55 A massive outbreak of CHIKV infection that began in Kenya in 2004 and spread over 4 years to the Indian Ocean islands, India, and Southeast Asia 55,56 redefined the virus' public health relevance and potential to cause widespread infection, including in more temperate regions. Between 1995 and 2009, 109 laboratory-confirmed cases of CHIKV were diagnosed in adult travelers in the United States returning from India and other endemic countries, the majority (97%) of which occurred after 2006. 57 The principal Aedes mosquito vector for CHIKV is found across the United States and Europe, underscoring the potential for the virus to spread to nonendemic regions of the Western hemisphere. An autochthonous outbreak (from human to mosquito to human) of CHIKV occurred in Italy in 2007 after a viremic traveler returned from India. 58 Similar to outbreaks of dengue in southern regions of the United States, an autochthonous CHIKV outbreak, heralded by infection in nontravelers, is certainly plausible. 57 In December 2013, the first cases of CHIKV in nontravelers in the Western hemisphere were reported in St Martin in the Caribbean. 59 Chikungunya virus causes an acute febrile illness characterized by severe arthralgia, typically of the distal joints, with or without rash. 56 Gait disturbance may result from involvement of the joints of the lower extremities, resulting in a broad-based, halting gait. 56 In returning travelers, CHIKV can be difficult to distinguish clinically from dengue fever and malaria, although arthralgias, particularly severe and more prolonged joint involvement, is more characteristic of CHIKV. In a large outbreak on the Indian Ocean island of La Reunion that began in March 2005, during which more than 47 000 cases per week occurred at its peak, the ability of the virus to cause neurologic disease became manifest. 60 In a retrospective, single-institution study in La Reunion, 19 (12%) of the 157 laboratory-confirmed cases of CHIKV had evidence of neurologic involvement, the majority of which were an acute confusional state. 61 Other neurologic manifestations include meningoencephalitis, acute flaccid paralysis, and Guillain-Barre syndrome. 60, [62] [63] [64] Although the case fatality rate is low, the infection is associated with significant morbidity and can lead to a debilitating, chronic syndrome of fatigue and joint pain. 65, 66 
Nipah Virus
Nipah virus, a paramyxovirus, was first identified in 1991 in a large encephalitis outbreak among pig farmers in Sungai Nipah, a village in the Malaysian peninsula in 1991. The wildlife reservoir of Nipah virus is bats of the genus Pteropus, which infect pigs. The virus is effectively transmitted from pig to pig and then can infect humans. This virus has caused outbreaks in Singapore, Australia, India, and Bangladesh. [67] [68] [69] Human disease can range from asymptomatic infection to fatal encephalitis. When neurologic illness occurs, individuals often experience an influenza-like illness followed by dizziness, excessive drowsiness, and altered conscious. Of particular concern is the discovery that Nipah can be transmitted from person-to-person, and nosocomial transmission has been described. 70 Although no cases have been identified in the United States, Nipah should be considered in individuals with recent travel to affected areas of the world. Both serologic and molecular methods are used for diagnosis and available through the CDC ( Table 1 ).
Hendra Virus
Hendra virus is a paramyxovirus first recognized in Hendra, Australia, where it was associated with an outbreak of respiratory and neurologic disease in horses and humans in 1994. The natural reservoir of the virus is thought to be flying foxes (bats of the genus Pteropus). The virus is transmitted from bats to horses to humans via direct contact with infected horses. More than 60 equine and 4 human fatalities have been reported. 71 Human illness due to Hendra virus is characterized by influenza-like symptoms often followed by acute encephalitis. A relapsing neurologic syndrome has also been described in a few individuals. 71 Diagnostic methods are similar to Nipah virus and are available through the CDC (Table 1) .
Cycloviruses
Recently, a novel virus genus, Cyclovirus of the Circovirdiae family, has been implicated as a new human pathogen using virus discovery techniques, including amplified fragment length polymorphism and next generation sequencing methods. Until the discovery of cycloviruses, there were only 2 known genera in the Circoviridae family: Circovirus type species and Gyrovirus type species. These viruses have been associated primarily with disease in animals, including birds and pigs and less commonly in dogs. Two patients in Vietnam were found to have a novel cyclovirus by pathogen discovery methodology. 72 After the identification of the new cyclovirus, CSF from additional patients with noninfectious and presumed infectious disorders was tested. None of the samples from patients with noninfectious disorders were found to have cyclovirus present, whereas cyclovirus was identified in 4% of 642 CSF samples from the presumed infectious group. However, several of these cases had an alternative diagnosis. In 2010 to 2011, cyclovirus was identified in a subset of 58 adult patients with paraplegia in Malawi. 73 Of the 54 patients, 8 (15%) and 5 of the 40 (1%) serum and CSF samples, respectively, were found to have cyclovirus by PCR methodology.
Cyclovirus has been detected in the blood of patients with febrile illnesses and acute flaccid paralysis. 74 Because cyclovirus has been isolated from the feces of healthy children, pigs, and chickens, a fecal-oral route of transmission has been proposed. Current information is insufficient to understand the role of cycloviruses in neurologic illness, and further study is needed.
Bacterial
Borrelia miyamotoi
Recent reports of human disease attributed to infection with Borrelia miyamotoi, a spirochete classified in the relapsingfever family, have raised the possibility that it may be an underrecognized cause of subacute to chronic meningoencephalitis in regions where Lyme is endemic. Gugliotta et al described a case of an elderly woman from rural New Jersey with non-Hodgkin lymphoma treated with chemotherapy, including rituximab in the months prior. 75 She had also previously been treated on 2 occasions for Lyme disease, the most recent of which was with doxycycline 5 years previously. Over a 4-month period, she developed progressive confusion, withdrawn personality, gait difficulty, hearing impairment, and weight loss. Neuroimaging was unremarkable while CSF analysis revealed a mild lymphocyte-predominant pleocytosis with significantly increased protein and a potentially borderline low glucose. Spirochetes were identified in the CSF on both Giemsa and Gram stains. Microscopic, immunofluorescence, and serological results were inconsistent with expected findings for Borrelia burgdorferi, Babesia microti, or Anaplasma phagocytophilum. The diagnosis was eventually made on the basis of a PCR assay on a CSF specimen that amplified 2 gene targets for B miyamotoi, confirmed by sequencing and phylogenetic analysis of the 16s ribosomal RNA and flagellin genes. After a 30-day course of intravenous penicillin G, the patient's mental status returned to her baseline and a posttreatment CSF sample was PCR negative.
Borrelia miyamotoi, a bacterium originally identified in Japan in 1995, 76 is genetically more closely related to the Borrelia species that cause relapsing fever than those that cause Lyme disease. However, unlike relapsing fever spirochetes that are transmitted by soft ticks, B miyamotoi is associated with hard-bodied ixodid ticks and has been shown to infect or coinfect a proportion of vector ticks that harbor Borrelia species associated with Lyme disease, 77, 78 although the clinical relevance of this is unclear. In Lyme endemic areas in the United States, the seroprevalence of B miyamotoi, detected with surveillance methods using a B miyamotoi-specific G1pQ protein, was 1% and up to 3.2% among patients with suspected Lyme disease. 79 The first case series of human disease associated with B miyamotoi was described in Russia, 80 and other nonimmunocompromised patients have also been described. 79 Not surprisingly given its genetic similarity with relapsing fever spirochetes, patients tended to present with a systemic febrile viral-like illness. Erythema migrans, the characteristic rash associated with Lyme disease, was infrequently present. 80 While nonspecific headache is a common feature, 80 the prevalence of neurologic involvement with B miyamotoi infection, as described by Gugliotta et al, is unknown. Two other recently reported cases in the United States have described associated leukopenia, thrombocytopenia, and elevated liver enzymes. 79 Primers used to detect Borrelia species that are responsible for Lyme disease may not amplify B miyamotoi given its closer genetic resemblance to relapsing fever spirochetes. Likewise, the accuracy of standard serological testing in discriminating between B miyamotoi and species that cause Lyme disease is unknown (Table 1) . 75, 79 A specific protein enzyme immunoassay (eg, using G1pQ antigen specific to B miyamotoi) may be needed to distinguish Lyme disease from this potentially emerging infection.
Neisseria meningitidis Outbreaks in the United States
Rates of bacterial meningitis in the United States have declined in the last decade due in large part to the introduction of highly effective vaccination programs. The incidence of meningitis caused by Neisseria meningitidis, which remains one of the most common causes of bacterial meningitis in older children and young adults, fell from 0.44 cases per 100 000 population between 1998 and 1999 to 0.19 cases between 2006 and 2007. 81 Because the quadrivalent meningococcal conjugate vaccine (MCV4) covers serogroups A, C, Y, and W-135 but not serogroup B, the relatively similar decline in rates across serogroups, including B, suggests that, in contrast to other causes of meningitis, the effect is unlikely to be attributable to the MCV4 vaccination program in the United States, 82 which was implemented in 2005 and recommended routine use of the vaccine in adolescents aged 11 to 18 years and anyone between 2 and 55 years at increased risk. 83 Despite the all-time low incidence of invasive meningococcal disease, 82 recent outbreaks have garnered particular attention in the United States and highlighted emerging issues surrounding the infection. Between August 2010 and February 2013, 22 cases of serogroup C invasive meningococcal disease among men who have sex with men (MSM) were identified and reported to the Department of Health and Mental Hygiene in New York City. One novel risk factor in the outbreak was meeting sexual partners through online social networking sites. The incidence of invasive disease in MSM between the age of 18 and 64 years in 2012 was 12.6 cases per 100 000 population versus 0.16 cases per 100 000 population in a comparable non-MSM age group. 84 Of the 22 cases, 12 were HIV infected but with relatively intact immune function overall. 85 Case fatality rates in outbreaks are often higher than with sporadic cases. 86 In New York, 7 men died, underscoring the importance of timely recognition of an outbreak and implementation of control measures.
Population-based surveillance data demonstrated a vaccine coverage rate of 74.0% among adolescents in the United States in 2012. 87 As uptake increases, a corresponding decline in the rates of meningitis due to serogroups A, C, Y, and W-135 covered by MCV4 may result. Two outbreaks, however, on university campuses in the United States in 2013, have highlighted the gap in coverage of the currently recommended vaccine for adolescents, with a huge proportion of meningococcal disease in the United States caused by group B strains. Beginning in March 2013, 8 cases of serogroup B meningococcal disease have been identified at Princeton University. 88 Several of the cases had evidence of meningitis. Similarly, at University of California Santa Barbara, 4 cases of serogroup B disease have been identified within a 3-week period in November 2013. 89 Although available in Europe, Canada, and Australia, a vaccine against serogroup B is not currently licensed in the United States. Several factors have hampered the development of a serogroup B vaccine, including homology between serogroup B and human polysaccharide glycoprotein epitopes, which results in poor immunogenicity and autoantigenicity. 90 However, an innovative new approach to vaccine development termed ''reverse vaccinology'' led to formulation of a vaccine with activity against serogroup B, although its widespread use in certain countries has been hindered by the economics of health care. 91 In the United States, Novartis has advanced a vaccine that covers serogroups A, B, C, Y, and W into the late stages of development.
Fungal
Cryptococcus gattii
An outbreak of 3 clonal subtypes (VGIIa, VGIIb, or VGIIc) of Cryptococcus gattii, a fungus found in soil and select trees, has been ongoing in British Columbia, Canada and the US Pacific Northwest since 2004. 92, 93 More recently, 25 cases of C gattii infection outside of the Pacific Northwest (Alabama, California, Florida, Georgia, Hawaii, Michigan, Montana, and New Mexico) have been reported, many of which have occurred in young, previously healthy men without any travel history to recognized areas of endemicity. 94 Thirteen of the reported cases were from California, where C gattii is now also considered to be endemic. The incidence of outbreak-associated and sporadic C gattii cases in the United States, however, is unknown, in part due to limitations in recognition and diagnosis to the species level of the infection. 95 Unlike the related and better-known species, Cryptococcus neoformans, which is a common cause of opportunistic infection in HIV-positive patients, C gattii rarely occurs in HIV-infected individuals. 96, 97 Additionally, the distribution of C gattii, which was previously thought to be found solely in tropical and subtropical climates (eg, Australia, New Zealand, Brazil, and Southeast Asia), is less widespread than C neoformans. 98 Infection with outbreak strains in the Pacific Northwest predominantly causes pulmonary disease in individuals with comorbid medical illnesses or underlying immune compromise, 92 while sporadic cases tend to involve the CNS, with or without concomitant pulmonary disease. 92, 94, 97 Headache, visual disturbance, nausea, cranial nerve palsies, and hydrocephalus are frequent presenting signs and symptoms. 94 The case fatality rate in the 25 sporadic cases was 24%. Female sex and cryptococcemia were associated with a greater risk of death. 94 
Parasitic
Free-Living Amoeba
Balamuthia mandrillis, Naegleria fowleri, and several species of Acanthamoeba have been known to cause encephalitis for a few decades. 99 Recently, a number of issues related to neurologic infections and free-living amoeba (FLA) have emerged: newly discovered types of FLA causing human illness, new routes of transmission, geographic expansion, and novel treatment options.
Free-living amoeba are ubiquitous in the environment, and many human cases result from exposure to either soil or water. The FLA that cause encephalitis classically are divided into 2 clinical entities: (1) primary amebic meningoencephalitis (PAM) due to N. fowleri (also known as ''the brain-eating amoeba'') and the newly recognized Paravahlkampfia francinae and (2) granulomatous amebic encephalitis. 100 Primary amebic meningoencephalitis, first described in Australia in 1965, is a fulminant, often fatal disease occurring in children and young adults. Since then, PAM has been detected in Europe, Asia, Africa, and North America. In the United States, most cases occur in the southern tier of the country due to warm water conditions. More recently, Minnesota (2010 and 2012), Kansas (2011), Indiana (2012), and Virginia [101] [102] [103] have reported human cases. Most reports of PAM occur after swimming, diving, or washing in warm, fresh water, leading to entry of contaminated water into the nose and migration to the brain. In 2011, 2 cases of PAM were identified in Louisiana in patients without a history of recreational water exposure. They had, however, used ''neti'' pots for nasal and sinus irritation; N fowleri-contaminated tap water was implicated as the source of infection. 102 The onset of PAM is usually within 2 to 7 days after exposure. Signs and symptoms are similar to bacterial meningitis, including severe headache, fever, stiff neck, nausea, vomiting, diplopia, seizures, behavioral changes, and coma. Distortion of taste or smell, often present in patients with PAM, may be helpful in distinguishing from bacterial meningitis. 99 The case fatality rate is extremely high; of the 111 reported cases in the United States between 1962 and 2008, only 1 individual survived. 102 In 2009, a new species of FLA was isolated from an 18-year-old man with onset of PAM after a swimming pool exposure. 100 Unlike cases due to N fowleri, this individual made a full recovery after only a few days of hospitalization. The authors suggest that previously reported PAM ''survivor'' cases may have been due to P francinae rather than N fowleri. 100, 104, 105 Like PAM, granulomatous amebic encephalitis (GAE) also has a poor prognosis but typically has a more subacute to chronic presentation. To date, 3 closely related amoeba genuses have been associated with granulomatous encephalitis: Acanthamoeba spp., Balamuthia mandrillaris, and Sappinia spp. Acanthamoeba granulomatous encephalitis is generally an opportunistic, chronic disease that may have a prodromal period of weeks to months. Historically, acanthamebiasis has been associated with autoimmune conditions, organ transplantation, chemotherapy, radiation therapy, alcoholism, pregnancy, and long-term corticosteriod use. Recently, increasing numbers of Acanthamoeba cases have been described in immunocompetent children and adults. [106] [107] [108] Clinical features of CNS Acanthamoeba infections are variable and may include fever, vomiting, headache, neck stiffness, seizures, ataxia, personality change or abnormal behavior, lethargy, and/or confusion. Cranial nerve palsies, meningeal signs, or hemiparesis may be seen on physical examination.
Balamuthia mandrillis was first reported as a cause of encephaliits in humans in 1980 and over 200 cases have been reported worldwide. Symptoms of Balamuthia GAE are similar to Acanthamoeba infection. Otitis media has preceded the onset of Balamuthia granulomatous encephalitis in several pediatric cases, and hydrocephalus is a common occurrence. 109 Of the cases recognized to date, most were initially thought to be due to other entities such as acute disseminated encephalomyelitis, stroke, progressive multifocal leukoencephalopathy, neurocysticercosis, and tuberculosis. 110 A new development in this field has been the recognition that Balamuthia can be transmitted via organs. Recent clusters of transplant-associated Balamuthia GAE have been recognized. 111, 112 Not only do these cases demonstrate the varied presentations of CNS Balamuthia, but they also illustrate the diagnostic challenge associated with the infection. The diagnosis was only realized after a few individuals developed neurologic illness and extensive studies were performed.
Treatment options for FLA are limited, and survival rates are poor. Of patients who have survived, treatment has generally included a combination of several drugs including antifungals, antiparasitics, and antibiotics, making it unclear which, if any, were effective. Miltefosine is an antileishmania drug and has shown some promise when used in combination with other drugs in the treatment of patients with FLA. 113 The CDC has recently expanded its investigational new drug protocol to provide miltefosine directly to clinicians to treat FLA infections of the CNS. 114 
Conclusion
In this article, we reviewed a group of emerging and reemerging pathogens that are either newly discovered or for which there is a specific novel issue. These infections are an important reminder of why the quote from decades ago stating it is ''time to close the book on infectious diseases, and declare the war against pestilence won'' was premature. Indeed, with novel pathogen discovery methods, changes in agricultural techniques, widespread international travel, and an increasingly immunocompromised patient population, the ''war against pestilence'' wages on.
